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Although inserting exogenous viral genome segments into rotavirus particles remains a hard
challenge, this study describes the in vivo incorporation of a recombinant viral capsid protein
(VP6) into newly assembled rotavirus particles. In vivo biotinylation technology was exploited to
biotinylate a recombinant VP6 protein fused to a 15 aa biotin-acceptor peptide (BAP) by the
bacterial biotin ligase BirA contextually co-expressed in mammalian cells. To avoid toxicity of VP6
overexpression, a stable HEK293 cell line was constructed with tetracycline-inducible expression
of VP6–BAP and constitutive expression of BirA. Following tetracycline induction and rotavirus
infection, VP6–BAP was biotinylated, recruited into viroplasms and incorporated into newly
assembled virions. The biotin molecules in the capsid allowed the use of streptavidin-coated
magnetic beads as a purification technique instead of CsCl gradient ultracentrifugation. Following
transfection, double-layered particles attached to beads were able to induce viroplasm formation
and to generate infective viral progeny.
INTRODUCTION
Rotavirus is the most common aetiological agent of
gastroenteritis in infants and young children worldwide
(Dennehy, 2008). The virion is a non-enveloped, triple-
layered particle (TLP) containing a genome of 11 segments
of dsRNA encoding six structural proteins (VP1–VP4, VP6
and VP7) and, depending on the virus strain, five or six
non-structural proteins (NSP1–NSP6) (Estes & Kapikian,
2007). The RNA genome together with the enzymes
required for transcription and genome replication (VP1
and VP3) are packaged inside the virion, surrounded by
three concentric protein layers (Chen et al., 1999; Liu et al.,
1992; Pizarro et al., 1991; Valenzuela et al., 1991). The
outer layer consists of VP7 with spikes of VP4 trimers,
whilst the intermediate layer is formed by VP6 and the
inner one by VP2 (Lawton et al., 1997a; Prasad et al., 1996).
Following cell entry, the outer-layer proteins VP4 and VP7
are removed, resulting in a double-layered particle (DLP)
that contains the second layer formed by 260 VP6 trimers
associated in a T13 levo-icosahedral lattice (Lawton et al.,
1997b). DLPs are transcriptionally active and yet require
the VP6 layer in addition to the enzymes directly involved
in RNA synthesis. The exact role of VP6 in this process is
not known (Bican et al., 1982; Charpilienne et al., 2002;
Feng et al., 2002; Lawton et al., 1999; Libersou et al., 2008;
Thouvenin et al., 2001). Furthermore, VP6 may have a role
during budding of DLPs from viroplasms, the cytoplasmic
virus factories in which they form, into the endoplasmic
reticulum where they acquire the third layer (Delmas et al.,
2004; Meyer et al., 1989; Taylor et al., 1992, 1993). The
crystal structure of VP6 has been determined (Mathieu
et al., 2001), and its interactions with the outer and inner
layers have been described by biochemical (Charpilienne
et al., 2002) and structural (Chen et al., 2009; Settembre
et al., 2011) studies. The VP6 monomer is folded into two
different domains, an upper b-barrel domain and an a-
helical domain, which participate in trimer stabilization
and interactions with the outer and inner layers of the
virion, respectively (Mathieu et al., 2001). The VP6 trimer
has a tower-like shape whose base shows a triangular cross-
section, whilst the head has a hexagonal cross-section. Each
of the three VP6 molecules exposes three loops (A9A0, BC
and HI) for interaction with the VP7 outer layer (Mathieu
et al., 2001). In the present work, we describe insertion into
the loop HI of an exogenous 15 aa biotin-acceptor peptide
(BAP) that allowed in vivo biotinylation of the modified
protein. The BAP peptide was specifically biotinylated in
vivo when contextually co-expressed in mammalian cells
with the Escherichia coli-derived biotin ligase, BirA (Beckett
et al., 1999). BirA covalently attaches a single biotin
molecule to a defined lysine residue within BAP. We have
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shown previously that both cytosolic and secretory BAP-
tagged proteins can be efficiently biotinylated when BirA
is targeted either to the cytosol or to the secretory path-
way, respectively (Petris et al., 2011; Predonzani et al.,
2008). Here, we describe the incorporation of in vivo-
biotinylated VP6–BAP into newly assembled viral particles
resulting in functional DLPs and TLPs decorated with
biotin molecules.
RESULTS AND DISCUSSION
In vivo-biotinylated VP6 trimerizes and localizes
in viroplasms
We constructed a recombinant VP6 protein by modifying a
site within loop HI, which should not be involved in
proper folding (Mathieu et al., 2001). The BAP peptide,
flanked by 2 aa upstream (SG) and 3 aa downstream
(GAS), was inserted between residues P309 and P313 of
VP6 from the simian rotavirus SA11 strain, replacing
residues N310, A311 and Q312, which are not involved in
intra-trimer contacts (Mathieu et al., 2001) (Fig. 1a). The
position in which BAP was inserted within the VP6
structure should allow the addition of biotin molecules on
the surface of DLPs.
In order to obtain recombinant viral particles containing
the BAP-tagged VP6 protein (VP6–BAP), rotavirus-
infected cells expressing this recombinant protein were
needed. Numerous attempts to obtain a stable cell line
constitutively expressing VP6–BAP failed, probably
because of the toxicity of the cytosolic tubules formed by
VP6 when overexpressed alone (Contin et al., 2010; Lepault
et al., 2001). To address this problem, the VP6–BAP gene
was cloned under the control of a tetracycline-inducible
promoter (TetOn). We used the Flp-In T-REx system (Life
Technologies) designed for rapid generation of stable
HEK293 cell lines through site-specific genome integration
mediated by the enzyme flippase (Flp) (O’Gorman et al.,
1991). A genetic construct was derived containing, in
addition to the tetracycline-inducible VP6–BAP gene, a
constitutive transcriptional unit for the cytosol-localized
enzyme BirA (cytBirA) (Fig. 1b). We first checked, by
transient transfection into HEK293 cells, whether VP6–
BAP was biotinylated by the BirA enzyme and was still
capable of forming trimers. As shown in the Western blot
retardation assay in Fig. 1(c, left panel), VP6–BAP was very
efficiently biotinylated by BirA. In this assay, proteins were
resolved by SDS-PAGE in the presence of streptavidin. The
complex formed by biotinylated proteins and streptavidin
is resistant to denaturing conditions and therefore only
biotinylated molecules showed a retarded migration. All
VP6–BAP molecules were found to be retarded, thus
indicating a biotinylation efficiency close to 100%. It was
also observed that VP6–BAP was able to form trimers (Fig.
1c, right panel), indicating that an important feature
required for proper assembly of the second layer in virus
particles was preserved.
A stable transfectant (HEK293/VP6–BAP) was then
established, containing two characteristics: (i) constitutive
expression of BirA, and (ii) tetracycline-inducible expres-
sion of VP6–BAP. The level of VP6–BAP expression,
however, was very low. In fact, as shown in Fig. 1(d),
although VP6–BAP could be detected with HRP-conju-
gated streptavidin, its expression level was below the
threshold for detection with the anti-VP6 serum, which
nevertheless reacted with wild-type VP6 in infected cells.
Therefore, in these cells, virus replication would take place
with a highly unbalanced contribution of VP6–BAP in
relation to the wild-type protein.
In spite of this, when these cells were induced with
tetracycline and infected the day after with rotavirus SA11
strain, we observed that VP6–BAP was able to localize in
viroplasms. As shown in Fig. 1(e), only after tetracycline
treatment was biotinylated VP6–BAP detected at the
periphery of viroplasms, which were stained with antibod-
ies reacting with the viroplasm-resident protein NSP5.
These results indicated that biotinylated VP6–BAP has the
capacity to be recruited into viroplasms, as occurs with the
wild-type protein.
In vivo-biotinylated VP6 is incorporated into
newly synthesized viral particles
In order to investigate whether VP6–BAP could also be
incorporated into viral particles, tetracycline-induced cells
were infected for 48 h (m.o.i. of 3), and newly formed viral
particles were then purified by CsCl gradient ultracentri-
fugation. Fractions of the gradient corresponding to TLPs,
DLPs and empty particles not containing the viral genome
(EPs) were analysed by Western blotting for the presence of
biotinylated VP6–BAP (Fig. 2a). VP6–BAP was found in all
three types of viral particles only when infection occurred
in the presence of tetracycline. Interestingly, both TLPs and
DLPs, distinguished because of the presence of VP7 in
TLPs, contained biotinylated VP6–BAP, indicating that the
presence of biotinylated VP6–BAP molecules in addition to
wild-type VP6 did not interfere with formation of the outer
shell. This finding was particularly important because,
according to reconstruction of the VP6–VP7 heterohex-
amer based on high-resolution electron cryo-microscopy
analysis of VP7-recoated DLPs, the VP6 loop containing
the biotinylated BAP should be in close contact with VP7
(Chen et al., 2009). Therefore, the small size of the tag used
may have been crucial in order not to compromise the
interaction with VP7. When observed by electron micro-
scopy (uranyl acetate staining), the morphology of viral
particles isolated from tetracycline-induced cells appeared
almost identical to those isolated from non-induced cells
(Fig. 2b). Furthermore, those fractions of the gradient
found to contain a mixture of TLPs and DLPs were
analysed by non-denaturing agarose gel electrophoresis in
MOPS buffer (Fig. 2c). Under these conditions, TLPs and
DLPs migrated as intact particles at different positions and
could be visualized by ethidium bromide staining because
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of their RNA genome content (Fig. 2c, upper panel). The
viral particles were then denatured by soaking the gel in a
1% SDS solution and transferred from the agarose gel to a
PVDF membrane in order to reveal the presence of
biotinylated VP6–BAP by reacting with HRP-conjugated
streptavidin. As expected, VP6–BAP was found in viral
particles derived from tetracycline-induced infected cells
and was absent in those coming from non-induced infected
cells (Fig. 2c, middle panel). Whilst both TLPs and DLPs
were shown to contain biotinylated VP6–BAP, biotin was
displayed only on the surface of DLPs, as the addition of
streptavidin-coated beads depleted them from the DLP/
TLP mixture (Fig. 2c, middle panel, lane 4). Taken
together, these data demonstrated that biotinylated VP6–
BAP was incorporated into newly assembled viral particles.
Purification of biotinylated DLPs with
streptavidin-coated magnetic beads
We took advantage of the high affinity between biotin and
streptavidin to purify DLPs containing biotinylated VP6–
BAP. We used magnetic beads coated with streptavidin on
crude viral preparations, previously dialysed and treated
with EDTA to convert TLPs into DLPs, thus increasing the
yield of DLPs bearing VP6–BAP. The purified material was
analysed by Western blotting with antibodies against VP1,
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Fig. 1. In vivo biotinylation of VP6–BAP. (a) Top: schematic representation of the linear amino acid sequence of VP6–BAP;
aa 310–312 (NAQ) were replaced with the 15 aa BAP peptide, indicated in the orange box, and the five amino acids used as
linkers (underlined). Bottom: ribbon diagram of the VP6 monomer indicating the loop HI where BAP was located. (b) Schematic
of the plasmid used to stably transfect Flp-In HEK293 cells resulting in constitutive expression of BirA and tetracycline-inducible
expression of VP6–BAP. (c) Left panel: Western blot retardation assay of cellular extracts of HEK293 cells transiently
transfected with the plasmid shown in (b) (lanes 5 and 6) or with the same plasmid without the BirA transcriptional unit cassette
(lanes 3 and 4), pre-incubated with or without streptavidin (StrAv) before PAGE and analysed with anti-VP6 serum; the arrow
indicates the shifted VP6–BAP molecules. Right panel: Western blot of biotinylated VP6–BAP revealed with streptavidin–HRP,
not boiled (lane 1) or boiled (lane 2) before PAGE to visualize VP6–BAP trimers and monomers, respectively; asterisks indicate
endogenous biotinylated proteins. (d) Western blot with anti-VP6 serum and streptavidin–HRP of extracts from tetracycline-
induced cells (Tet-ind.) or virus-infected cells (Infected). (e) Confocal microscopy of Flp-In HEK293 cells stably transfected
with the plasmid shown in (b), induced or not with tetracycline for 24 h, infected with rotavirus SA11 strain, and analysed for the
presence of viroplasms (anti-NSP5, red) and biotinylated VP6–BAP (streptavidin–Alexa Fluor 488, green) at 5 h post-infection
(p.i.).
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VP2, VP7 and VP6 and with HRP-conjugated streptavidin.
As shown in Fig. 3(a), successful purification of DLPs
produced in tetracycline-induced cells was achieved in a
single affinity-purification step, as revealed by Western
blotting for the structural proteins VP1, VP2 and VP6. As
expected, no biotinylated VP6–BAP was found in the
unbound material (Fig. 3a, lane 5), represented by DLPs
not containing VP6–BAP plus all viral proteins in excess,
including soluble VP7 derived from the EDTA treatment.
The absence in the purified material of NSP5, a viral
protein abundantly expressed during infection but not
incorporated in mature virions, further confirmed the
specificity of the purification method. These results
indicated that purification with streptavidin-coated mag-
netic beads can be used directly to obtain DLPs from total
crude preparations, without the need for laborious CsCl
ultracentrifugation. Comparing the yield of VP1 recovered
in the purified fraction in relation to the unbound fraction,
we estimated that around 35% of all DLPs produced
contained VP6–BAP and were therefore purified by the
beads (Fig. 3a, compare the band intensity of VP1 in lanes
3 and 5). This quantification, however, underestimates the
percentage of biotinylated viral particles because it also
takes into account soluble viral proteins present in the
unbound fraction. A better estimate was obtained by
comparing VP1 levels between DLPs that were previously
purified by CsCl gradient ultracentrifugation from tetra-
cycline-induced and virus-infected cells under the same
conditions as before, and then precipitated with strepta-
vidin-coated magnetic beads. As shown in Fig. 3(b),
around 90% of DLPs contained VP6–BAP. Instead,
CsCl-purified TLPs showed a lower level of particles
containing VP6–BAP. As shown in Fig. 3(c), TLPs
containing VP6–BAP represented around 40% of the
total. In order to determine the relative abundance of
recombinant VP6–BAP (in relation to VP6) incorporated
in DLPs, we used particles purified with streptavidin-
coated magnetic beads to isolate only DLPs containing
biotinylated VP6–BAP. The precipitated material was
denatured by boiling in the presence of SDS, and both
biotinylated VP6–BAP and VP6 were detected in Western
blots (Fig. 3d). We took advantage of the different
migration of VP6–BAP and VP6 in PAGE to reveal the
two proteins with the same anti-VP6 antibody. Comparing
the intensity of VP6–BAP in Fig. 1(d, lane 1) with that of
VP6 in the serial dilutions, we estimated that VP6–BAP
represented around 1–3% of the total VP6. Thus,
considering that VP6 is present in 780 copies per particle,
DLPs were decorated, on average, with around eight to 25
biotin molecules per particle. This level of incorporated
recombinant protein was the consequence of the very low
expression of VP6–BAP in tetracycline-induced cells, as
mentioned above (Fig. 1d).
In addition, as VP6–BAP was also observed in TLPs, the
low incorporation rate may determine a condition of
permissiveness for the assembly of the VP7–VP4 outer
shell, in spite of the position in which BAP was inserted.
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Fig. 2. Incorporation of biotinylated VP6–BAP into newly
assembled viral particles. (a) Purification of rotavirus particles
(TLPs, DLPs and EPs) by CsCl gradient ultracentrifugation and
analysis by Western blotting with the indicated antibodies and
with streptavidin–HRP. Viral particles were obtained from the
SA11-infected HEK293/VP6–BAP stable cell line, induced or
not with tetracycline (TET). (b) Electron microscopy (uranyl
acetate staining) of DLPs purified as described in (a) from
tetracycline-induced (upper panel) or non-induced (lower panel)
HEK293/VP6–BAP cells. Bars, 100 nm (left panels); 50 nm
(right panels). (c) DLPs and TLPs resolved by non-denaturing
agarose gel electrophoresis and visualized by viral genome
staining with ethidium bromide (Eth.Br.) (upper panel) and, after
blotting onto a PVDF membrane, with anti-VP6 serum and, after
stripping, with streptavidin–HRP (lower and middle panels,
respectively). Where indicated, streptavidin-coated beads were
added to sequester particles displaying biotin on their surface.
The black arrow indicates the absence of biotinylated DLPs in
lane 4.
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Viral particles containing biotinylated VP6–BAP
are functional
In order to determine whether the affinity-purified DLPs
were functionally active, we transfected them into cells
and analysed their ability to form viroplasms and to
produce infective particles. As shown in Fig. 4(a),
transfection of DLPs not detached from beads led to the
formation of viroplasms, as revealed at 5 h post-transfec-
tion with anti-NSP5 antibodies. The magnetic beads could
be visualized in transfected cells, as indicated with arrows
in Fig. 4. The formation of viroplasms was only observed
when magnetic beads were incubated with crude extracts
containing DLPs produced in tetracycline-induced cells
but not with those containing DLPs from non-induced
cells (Fig. 4b). As treatment with EDTA removed nearly all
VP7 molecules, as verified by Western blotting (Fig. 3a), it
is unlikely that the observed viroplasms were the
consequence of traces of infective TLPs. Indeed, a negative
result was obtained by exposing cells to DLPs in the
absence of the transfection reagent, ruling out this
possibility (data not shown).
From a parallel transfection of DLPs containing VP6–BAP,
crude cellular extracts were prepared at 24 h post-
transfection and tested for the presence of infective
particles. Residual particles still attached to the magnetic
beads were removed before infection. Following activation
with trypsin, infection of MA104 cells was assessed by
detection of viroplasms with anti-NSP5 antibodies. Fig.
4(c) shows that infective viral particles were indeed
produced following transfection of the affinity-purified
DLPs but not of control beads incubated with material
deriving from non-induced cells.
To address whether TLPs containing VP6–BAP were also
functional, we determined the infectivity of CsCl-purified
TLPs from tetracycline-induced and non-induced cells.
The amount of TLPs resulting from each condition used
was normalized against VP1 and VP2 content. As shown in
Fig. 4(d), TLPs containing biotinylated VP6 were as
infective as TLPs not containing the recombinant protein.
In conclusion, whilst an effective and flexible methodology
to obtain recombinant rotavirus is not yet available, we
have succeeded in incorporating a recombinant viral
protein into virions by its overexpression in infected
mammalian cells. We have already reported previously the
incorporation of a recombinant tagged VP1 protein
following a combined transfection and infection procedure
(Arnoldi et al., 2007). In this case, viral particles were
decorated with biotin on their surface through an in vivo
biotinylation strategy that can readily be transferred to
other viral proteins and to other viruses. In this regard, the
in vivo biotinylation of the rotavirus spike protein VP4 is
under investigation with the aim of obtaining infective
biotinylated viral particles. In addition, the viroplasm-
resident protein NSP5 has already been shown to be
biotinylated successfully in vivo (Predonzani et al., 2008),
and attempts to use streptavidin-coated magnetic beads to
purify viroplasms are ongoing, as these virus factories are
still not well characterized.
Several different applications of this technique can be
envisaged. For instance, virus tropism may be modified by
exploiting the multivalent binding sites of streptavidin to
contextually attach biotin-decorated viral particles and
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blot with the anti-VP6 serum of serially diluted DLPs containing
VP6–BAP purified with streptavidin-coated magnetic beads. In all
cases, the band intensities were quantified using ImageJ software.
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biotinylated ligands of specific cell-surface internalizing
receptors. Moreover, decorated viral particles could be
used to sort virus-specific B cells carrying membrane
immunoglobulins reacting with virus-assembled proteins
within the particle or to identify viral receptors or host-
interacting partners.
METHODS
Cells and viruses. MA104 cells and HEK293 cells were grown as
monolayers in Dulbecco’s modified Eagle’s medium (DMEM; Life
Technologies) containing 10% FBS (Life Technologies) and 50 mg
gentamicin (Societa` Prodotti Antibiotici Biodivision) ml21. Flp-In
HEK293 cells (Flp-In T-REx system; Life Technologies), containing
the single genomic FRT site for Flp-mediated recombination and
transfected for stable expression of the tetracycline repressor (Glatter
et al., 2009), were grown in DMEM containing 10% FBS, 50 mg
gentamicin ml21, 15 mg blasticidin (InvivoGen) ml21 and 100 mg
zeocin (InvivoGen) ml21. Once stably transfected with the pcDNA5-
FRT-TO-VP6-BAP-cytBirA plasmid (see below), they were grown in
DMEM containing 10% FBS, 50 mg gentamicin ml21, 15 mg
blasticidin ml21 and 100 mg hygromycin (InvivoGen) ml21. The
simian rotavirus SA11 strain (G3, P6[1]) was propagated in MA104
cells, as described previously (Estes, 2001). Virus titres were
determined by immunofluorescence of MA104-infected cells with
anti-NSP5 antibodies and expressed as fluorescence-forming units
(f.f.u.) ml21, as described previously (Campagna et al., 2005).
For infectivity assays, normalization of the amount of TLPs from
tetracycline-induced and non-induced cells was performed by
determination of protein content using a Qubit Protein Assay kit
(Life Technologies) and by quantification of VP1 and VP2 content by
Western blotting and analysis of the band intensities using ImageJ
software (http://rsb.info.nih.gov/ij/).
Quantification of infected cells was performed using an ImageXpress
Micro automated high-content screening microscope (Molecular
Devices) equipped with a 620 objective. Automated image analysis
of viroplasm formation was performed using MetaXpress software
(Molecular Devices) using the Transfluor application module, which
identifies cell nuclei and cells containing viroplasms, thus allowing
calculation of viral titres.
Construction of plasmids. The VP6-coding sequence was derived
from rotavirus SA11 strain (G3, P6[1]) and amplified in two sections by
PCR. The first section was obtained using primers VP6(1)for (59-
ACCCAAGCTTGGTACCA24TGGATGTCCTA-39) and VP6(1)rev (59-
ATAGATATCACTTGTCCGGAC950GGGAATAGTACTGC-39 (restric-
tion sites are underlined and superscript numbers indicate the position
in the SA11 segment 6 of the nucleotides in bold). The amplicon was cut
using restriction enzymes HindIII and EcoRV and inserted into plasmid
pcDNA3 (Life Technologies), previously digested with the same
enzymes, producing plasmid pcDNA3-VP6/I. The second section was
obtained using primers VP6(2)for (59-ATATCCGGAACTTGGCTAG-
CC(960)CATTCGAACATCATGCA-39) and VP6(2)rev (59-ATGGATA-
TCT(1217)CATTTAATGAGCATGCTTCT-39) (underlining and super-
script numbers as above). The amplicon was cut with BspEI and EcoRV
and inserted into plasmid pcDNA3-VP6/I previously digested with the
same enzymes, producing plasmid pcDNA3-VP6. The oligonucleotide
encoding the BAP peptide (shown in upper case: 59-ttcggaGG-
CCTGAACGATATTTTCGAAGCTCAGAAAATCGAATGGCACGA-
Aggcgctagc-39; restriction sites underlined) was cloned into
pcDNA3-VP6 using BspEI and NheI, producing plasmid pcDNA3-
VP6-BAP. The complete VP6–BAP sequence was transferred into
plasmid pcDNA5-FRT-TO (Life Technologies) using HindIII and
EcoRV, thus obtaining plasmid pcDNA5-FRT-TO-VP6-BAP.
For cloning of the entire transcriptional unit of the birA gene, the
bacterial genome was extracted from E. coli XL1Blue strain
(Stratagene) as follows. The cell pellet was resuspended in TE buffer
[50 mM Tris/HCl (pH 8), 20 mM EDTA], the cells were lysed with
2% Sarcosyl and the protein components were removed by treatment
with 500 mg Pronase (Roche) ml21 at 37 uC for 10 min. DNA was
extracted with phenol : chloroform : isoamyl alcohol (25 : 24 : 1) and
precipitated with 2-propanol. The birA-encoding sequence was
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Fig. 4. Viral particles containing VP6–BAP are functional. (a, b)
Immunofluorescence with anti-NSP5 antibodies (red) of MA104
cells lipofected with biotinylated DLPs and analysed at 5 h post-
transfection. DLPs from tetracycline-induced (a, b;+TET) or non-
induced (b; ”TET) SA11-infected HEK293/VP6–BAP cells were
purified with streptavidin-coated magnetic beads. DLPs were
lipofected without being detached from the beads, which are easily
recognizable in the fluorescence microscopy images, as indicated
by the white arrows. (c) Immunofluorescence with anti-NSP5
antibodies (red) of MA104 cells at 5 h p.i. with viral crude
preparations obtained from DLP-lipofected MA104 cells. Viral
particles were collected at 24 h post-transfection. (d) Infectivity of
normalized equivalent aliquots of CsCl-purified TLPs derived from
tetracycline-induced (red line) or non-induced (blue line) HEK293/
VP6–BAP cells. The insert shows Western blot analysis of the
protein content (VP1, VP2 and VP7) in normalized aliquots of TLPs
used for infection experiments.
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amplified using primers BirA-F (59-CGGAATTCTACCATGAAGG-
ATAACACCGTGCCA-39) and BirA-R (59-AGACTCGAGTTATTTT-
TCTGCACTACGCAGGGA-39) (restriction sites underlined) and the
amplicon was cloned into pcDNA3 using EcoRI and XhoI, producing
plasmid pcDNA3-cytBirA. This was subsequently mutated to create a
BglII site downstream of the transcriptional unit of the birA gene in
addition to that already present upstream. To obtain plasmid
pcDNA5-FRT-TO-VP6-BAP-cytBirA, the entire transcriptional unit
of the birA gene was first cloned into pcDNA3-VP6-BAP digested
with BglII and then transferred from this plasmid to the pcDNA5-
FRT-TO-VP6-BAP vector using SpeI digestion.
Molecular images. The image of the VP6 secondary structure of the
bovine RF strain of rotavirus (Protein Data Bank accession code
1QHD) was rendered using Visual Molecular Dynamics (VMD)
software (Humphrey et al., 1996).
Transfections. The pcDNA5-FRT-TO-VP6-BAP-cytBirA plasmid
was transfected transiently in HEK293 cells or stably in Flp-In
HEK293 cells by a calcium phosphate technique, as described
previously (Eichwald et al., 2004). The stable cell line HEK293/
VP6–BAP was obtained by co-transfecting the pOG44 vector
encoding Flp (Life Technologies) with pcDNA5-FRT-TO-VP6-BAP-
cytBirA. For DLP transfection, DLPs bound to the streptavidin-coated
magnetic beads used for their purification (one-twelfth of the purified
material was used) were diluted in 100 ml Opti-MEM medium (Life
Technologies) and incubated with 4 mg Plus Reagent (Life
Technologies) for 5 min at room temperature. Lipofectamine Plus
(12 mg; Life Technologies) was then added and, after incubation for
30 min at room temperature, the final mixture was applied to
confluent monolayers of MA104 cells in 24-well plates (Ciarlet et al.,
2002).
Western blot analysis and retardation assay. Components of
cellular extracts and purified viral particles were separated by SDS-
PAGE (Laemmli, 1970) using Precision Plus Protein Standards
molecular mass markers (Bio-Rad). After electrophoresis, samples
were transferred to PVDF membranes (Millipore) (Towbin et al.,
1979). The membranes were incubated with the following antibodies
(obtained as described previously by Arnoldi et al., 2007 and Contin
et al., 2010): anti-VP1 guinea pig serum (diluted 1 : 5000), anti-VP2
guinea pig serum (1 : 5000), anti-VP7 rabbit serum (1 : 1000) and
anti-NSP5 guinea pig serum (1 : 8000). The anti-VP6 guinea pig
serum (1 : 2500) was kindly provided by Dr Alfred Metzler (Institute
of Virology, University of Zurich, Switzerland). For detection of
biotinylated VP6–BAP, streptavidin–HRP (1 : 1000; Jackson
ImmunoResearch) was used. Membrane stripping was performed
using ReBlot Plus Strong Solution (Millipore) following the
manufacturer’s instructions. To estimate the relative amount of
biotinylated versus non-biotinylated VP6–BAP protein, a gel
retardation assay was performed, as described previously
(Predonzani et al., 2008; Viens et al., 2004). For quantification of
the intensity of the bands, ImageJ software was used.
Tetracycline induction and in vivo biotinylation. Expression of
VP6–BAP was induced in HEK293/VP6–BAP cells by treatment with
1 mg tetracycline (Sigma) ml21 for 24 h before rotavirus infection.
Tetracycline induction was performed in the presence of 100 mM
biotin (Sigma), which was added to the culture medium to support
the in vivo biotinylation mediated by the constitutively expressed BirA
enzyme (Predonzani et al., 2008).
Purification of viral particles. Viral particles were purified from cell
culture when a complete cytopathic effect was reached. The virus was
pelleted by ultracentrifugation and the pellet extracted with
trichlorotrifluoroethane (Freon; Sigma Aldrich) and separated by
ultracentrifugation in a CsCl gradient, as described previously (Patton
et al., 2000). Fractions of 500 ml were pelleted and resuspended in
60 ml PIPES buffer (pH 6.6) containing 10 mM CaCl2.
Biotinylated viral particles were purified from fractions of the
gradient or directly from crude virus preparations using Dynabeads
MyOne Streptavidin T1 (Life Technologies). The magnetic beads were
pre-incubated with 1% BSA in PIPES buffer for 30 min and
incubated with the viral particles for 1 h at 4 uC. The beads were
washed three times with 0.1% BSA in PIPES buffer and resuspended
in 60 ml PIPES buffer. One-sixth of the purified material was eluted by
heating at 95 uC for 15 min and analysed by Western blotting,
whereas one-twelfth was used for DLP transfection without detaching
the viral particles from the beads.
For purification from crude virus preparations, the virus was pelleted,
extracted with Freon, treated with 20 U DNase I (Fermentas) and
20 U RNase ONE (Promega) and finally treated with EDTA as
described below. Biotinylated viral particles were isolated using
streptavidin-coated magnetic beads, as described above.
EDTA treatment. Virus preparations were dialysed against water and
treated with 5 mM EDTA in PIPES buffer for 30 min at 37 uC using a
modification of a previously described procedure (Estes et al., 1979).
The resulting particles were pelleted by ultracentrifugation and
analysed by Western blotting.
Analysis of viral particles by native agarose gel electrophoresis
and electroblotting. The viral particle content of TLPs and DLPs
was analysed by electrophoresis on a non-denaturing 1% agarose gel
in MOPS buffer (pH 7.25) using a modification of a previously
described procedure (Charpilienne et al., 2001). The RNA content of
viral particles was revealed by soaking gels in a solution containing
0.1 mg ethidium bromide ml21. The gels were then incubated for 1 h
in transfer buffer [250 mM glycine, 25 mM Tris/HCl (pH 8), 20%
methanol] supplemented with 1% SDS. Viral proteins were
electroblotted onto PVDF membranes (50 mA, overnight). The
membranes were then treated as described above for Western
blotting.
Fluorescence microscopy. At 5 h p.i. and post-transfection,
microscopy experiments were performed as described previously
(Eichwald et al., 2002) with the following antibodies: anti-NSP5
guinea pig serum (diluted 1 : 1000) (Gonza´lez & Burrone, 1991),
rhodamine (TRITC)-conjugated anti-guinea pig secondary antibody
(1 : 200) and streptavidin–Alexa Fluor 488 (1 : 1000) (both from
Jackson ImmunoResearch). Cell nuclei were stained with 2 mg
Hoechst 33342 (Life Technologies) ml21. Samples were analysed by
confocal microscopy (LSM 510; Carl Zeiss) or using a cool SNAPs
system using a fluorescence microscope (DMLB; Leica).
Electron microscopy. DLPs were adsorbed for 10 min to carbon-
coated Parlodion films mounted on 300 mesh per inch copper grids
(EMS). Samples were washed once with distilled water and stained
with saturated uranylacetate (Fluka) for 5 min at room temperature.
Specimens were analysed in a transmission electron microscope (CM
12; Philips) equipped with a CCD camera (Ultrascan 1000; Gatan) at
an acceleration voltage of 100 kV.
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